GRNA: AI 评分 57/100 — AI 分析 (4月 2026)

GreenLight Biosciences Holdings is a biotechnology company focused on developing RNA-based solutions for human health and agriculture. The company aims to provide innovative and sustainable products through its proprietary RNA platform.

Key Facts: AI Score: 57/100 Sector: Healthcare

公司概况

概要：

GreenLight Biosciences Holdings is a biotechnology firm specializing in RNA-based solutions for both human health and agricultural applications, offering mRNA vaccines and crop protection products. With a focus on sustainability and innovation, the company operates in a competitive landscape, marked by significant growth potential and inherent regulatory complexities.

GRNA是做什么的？

Founded in 2008 and headquartered in Medford, Massachusetts, GreenLight Biosciences Holdings is a biotechnology company dedicated to developing and commercializing RNA-based solutions. The company operates at the intersection of human health and agriculture, leveraging its proprietary RNA platform to create innovative and sustainable products. In the human health sector, GreenLight Biosciences focuses on mRNA vaccines and therapeutics, aiming to address a range of diseases and improve patient outcomes. Its agricultural applications include RNA-based products designed to protect crops and honeybees, promoting sustainable farming practices and reducing reliance on traditional chemical pesticides. GreenLight Biosciences's mission is to provide effective and environmentally friendly alternatives to conventional methods in both healthcare and agriculture. The company's approach involves designing and manufacturing RNA molecules that can target specific biological processes, offering precise and efficient solutions. This technology has the potential to revolutionize various industries by providing sustainable and targeted interventions. The company's focus on RNA technology positions it within a rapidly evolving field, marked by increasing investment and scientific advancements. GreenLight Biosciences continues to invest in research and development to expand its product pipeline and address unmet needs in its target markets.

GRNA的投资论点是什么？

GreenLight Biosciences Holdings presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's RNA-based platform offers potential for significant growth in both human health and agriculture. Key value drivers include successful development and commercialization of its mRNA vaccines and therapeutics, as well as its agricultural RNA products. The company's gross margin is currently 100.0%. Upcoming catalysts include potential regulatory approvals for its pipeline products and strategic partnerships to expand its market reach. However, the company's negative P/E ratio of -0.24 and a substantial negative profit margin of -2616.8% highlight the financial challenges and risks associated with investing in early-stage biotechnology companies. Investors should closely monitor the company's cash burn rate, regulatory milestones, and competitive landscape.

GRNA在哪个行业运营？

GreenLight Biosciences operates in the rapidly evolving biotechnology industry, characterized by intense competition and significant growth potential. The market for RNA-based therapeutics and agricultural solutions is expanding, driven by advancements in technology and increasing demand for sustainable products. The company competes with established pharmaceutical companies and other biotechnology firms, including ALVR, BLUE, ERYP, LIANY, and MGTA. The industry is subject to stringent regulatory requirements and faces challenges related to clinical trials, manufacturing, and market access. GreenLight Biosciences's success depends on its ability to innovate, secure regulatory approvals, and establish strategic partnerships.

Biotechnology

Healthcare

GRNA有哪些增长机遇？

Expansion of mRNA Vaccine Pipeline: GreenLight Biosciences has the opportunity to expand its mRNA vaccine pipeline to address a wider range of infectious diseases. The global vaccine market is projected to reach $100 billion by 2025, driven by increased awareness of preventative healthcare and advancements in vaccine technology. Successful development and commercialization of new mRNA vaccines could generate significant revenue streams for the company. The timeline for this growth opportunity depends on clinical trial outcomes and regulatory approvals.
Agricultural RNA Products for Crop Protection: The company can further develop and commercialize its agricultural RNA products to protect crops from pests and diseases. The market for crop protection products is estimated at $70 billion annually, with increasing demand for sustainable and environmentally friendly solutions. GreenLight Biosciences's RNA-based products offer a targeted and biodegradable alternative to traditional chemical pesticides, providing a competitive advantage. The timeline for this growth opportunity depends on field trial results and regulatory approvals.
Strategic Partnerships and Collaborations: Forming strategic partnerships and collaborations with established pharmaceutical companies and agricultural firms can accelerate the development and commercialization of GreenLight Biosciences's products. These partnerships can provide access to funding, expertise, and distribution networks, enhancing the company's market reach and competitive position. The timeline for this growth opportunity depends on the negotiation and execution of partnership agreements.
Geographic Expansion into Emerging Markets: Expanding into emerging markets, such as Asia and Latin America, presents a significant growth opportunity for GreenLight Biosciences. These markets have a growing demand for innovative healthcare and agricultural solutions, driven by increasing populations and rising incomes. The timeline for this growth opportunity depends on market entry strategies and regulatory approvals in each target country.
Development of RNA-based Therapeutics: GreenLight Biosciences can leverage its RNA platform to develop novel therapeutics for various diseases, including cancer and genetic disorders. The market for RNA-based therapeutics is projected to reach $25 billion by 2028, driven by advancements in RNA technology and increasing investment in drug development. Successful development and commercialization of new RNA-based therapeutics could generate substantial revenue streams for the company. The timeline for this growth opportunity depends on clinical trial outcomes and regulatory approvals.

Market capitalization of $0.05 billion, indicating a small-cap company with potential for growth but also higher volatility.
Gross margin of 100.0%, reflecting the company's ability to efficiently produce its RNA-based products.
Negative P/E ratio of -0.24, suggesting the company is currently not profitable.
Profit margin of -2616.8%, highlighting significant expenses relative to revenue.
Beta of 1.44, indicating higher volatility compared to the overall market.

GRNA提供哪些产品和服务？

Manufactures RNA products for human health applications.
Develops mRNA vaccines to combat infectious diseases.
Creates mRNA therapeutics for treating various illnesses.
Produces agricultural RNA products to protect crops.
Offers RNA-based solutions for honeybee health.
Focuses on sustainable and environmentally friendly alternatives.
Utilizes a proprietary RNA platform for targeted interventions.

GRNA如何赚钱？

Develops and manufactures RNA-based products.
Generates revenue through product sales to healthcare providers and agricultural businesses.
Forms partnerships and collaborations for research and development.
Seeks regulatory approvals for its products in various markets.

Healthcare providers and hospitals.
Agricultural businesses and farmers.
Government agencies and research institutions.
Pharmaceutical companies (through partnerships).

Proprietary RNA Technology Platform: GreenLight Biosciences's proprietary RNA technology platform provides a competitive advantage by enabling the rapid and efficient development of RNA-based products.
Intellectual Property Portfolio: The company's intellectual property portfolio, including patents and trade secrets, protects its technology and products from competition.
First-Mover Advantage: GreenLight Biosciences has a first-mover advantage in certain segments of the RNA-based solutions market, particularly in agricultural applications.
Strategic Partnerships: Strategic partnerships with established companies provide access to funding, expertise, and distribution networks.

什么因素可能推动GRNA股价上涨？

Upcoming: Regulatory approvals for mRNA vaccine candidates.
Upcoming: Positive results from clinical trials of RNA-based therapeutics.
Ongoing: Expansion of strategic partnerships and collaborations.
Ongoing: Advancement of agricultural RNA product development.

GRNA的主要风险是什么？

Potential: Clinical trial failures or delays.
Potential: Regulatory hurdles and rejection of product approvals.
Ongoing: Intense competition from established companies.
Ongoing: Financial risks associated with high operating expenses and negative profitability.

GRNA的核心优势是什么？

Proprietary RNA technology platform.
Innovative and sustainable product offerings.
Potential for high growth in both human health and agriculture.
Experienced management team.

GRNA的劣势是什么？

Negative profitability and high operating expenses.
Reliance on regulatory approvals.
Limited commercialized products.
Small market capitalization.

GRNA有哪些机遇？

Expansion of mRNA vaccine pipeline.
Development of RNA-based therapeutics.
Strategic partnerships and collaborations.
Geographic expansion into emerging markets.

GRNA面临哪些威胁？

Intense competition from established pharmaceutical and biotechnology companies.
Regulatory hurdles and clinical trial risks.
Technological advancements by competitors.
Economic downturns and market volatility.

GRNA的竞争对手是谁？

Allovir Inc — Focuses on developing allogeneic T-cell therapies. — (ALVR)
Bluebird Bio Inc — Develops gene therapies for severe genetic diseases. — (BLUE)
Erytech Pharma SA — Develops therapies by encapsulating therapeutic substances inside red blood cells. — (ERYP)
LianBio — Focuses on bringing innovative medicines to patients in China and other Asian markets. — (LIANY)
Magenta Therapeutics Inc — Develops stem cell therapies to reset the immune system for patients with immune and blood disorders. — (MGTA)

Key Metrics

MoonshotScore: 57/100

Company Profile

CEO: Andrey Juan Zarur
Headquarters: Medford, US
Employees: 280
Founded: 2022

AI Insight

AI analysis pending for GRNA

常见问题

What does GreenLight Biosciences Holdings do?

GreenLight Biosciences Holdings is a biotechnology company that develops and manufactures RNA-based products for both human health and agricultural applications. In human health, they focus on mRNA vaccines and therapeutics, aiming to address various diseases. For agriculture, they create RNA-based solutions to protect crops and honeybees, promoting sustainable farming practices. The company leverages its proprietary RNA platform to offer targeted and environmentally friendly alternatives to conventional methods, positioning itself as an innovator in the biotechnology sector.

What do analysts say about GRNA stock?

Analyst coverage of GreenLight Biosciences Holdings (GRNA) is still emerging, reflecting its relatively early stage as a publicly traded company. Key valuation metrics, such as its negative P/E ratio, suggest that the company is currently not profitable, which is common for biotechnology firms investing heavily in research and development. Growth considerations center around the successful development and commercialization of its RNA-based products, as well as its ability to secure regulatory approvals and strategic partnerships. Investors should conduct their own due diligence and consider the risks and uncertainties associated with investing in early-stage biotechnology companies.

What are the main risks for GRNA?

GreenLight Biosciences Holdings faces several key risks inherent to the biotechnology industry. These include the potential for clinical trial failures or delays, regulatory hurdles and the risk of product approval rejection, and intense competition from established pharmaceutical and biotechnology companies. Additionally, the company faces financial risks associated with high operating expenses, negative profitability, and the need to raise additional capital to fund its research and development activities. These risks are compounded by the volatile nature of the biotechnology market and the potential for technological advancements by competitors.

How does GreenLight Biosciences Holdings navigate regulatory approval processes?

GreenLight Biosciences Holdings navigates regulatory approval processes by adhering to stringent guidelines set by regulatory agencies such as the FDA and EMA. The company conducts rigorous preclinical and clinical trials to demonstrate the safety and efficacy of its RNA-based products. GreenLight Biosciences also maintains a dedicated regulatory affairs team that works closely with regulatory agencies to ensure compliance with all applicable regulations. The company's strategy includes proactive communication with regulatory bodies, comprehensive documentation, and a commitment to transparency throughout the approval process.

What are the key growth opportunities for GRNA in healthcare?

GreenLight Biosciences Holdings has several key growth opportunities in the healthcare sector. These include expanding its mRNA vaccine pipeline to address a wider range of infectious diseases, developing novel RNA-based therapeutics for various diseases, and forming strategic partnerships with established pharmaceutical companies to accelerate the development and commercialization of its products. The company can also explore geographic expansion into emerging markets with unmet medical needs. Successful execution of these growth strategies could significantly enhance GreenLight Biosciences's market position and revenue streams.